Charles Schwab Investment Management Inc Akebia Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

$429 Billion
Q1 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 79,804 shares of AKBA stock, worth $81,400. This represents 0.0% of its overall portfolio holdings.

Number of Shares

79,804

Previous 79,804 -0.0%

Holding current value

$81,400

Previous $98,000 48.98%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.56 - $1.15 $29,436 - $60,450	-52,566 Reduced 39.71%	79,804 $44,000
Q3 2022 Nov 14, 2022	BUY	$0.32 - $0.46 $42,358 - $60,890	132,370 New	132,370 $42,000
Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.67 $152,631 - $319,572	-476,974 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$0.72 - $2.93 $23,771 - $96,736	33,016 Added 7.44%	476,974 $343,000
Q3 2021 Nov 16, 2021	SELL	$2.35 - $3.88 $1.55 Million - $2.55 Million	-658,251 Reduced 59.72%	443,958 $1.28 Million

Q2 2021 Aug 16, 2021	BUY	$2.83 - $4.2 $246,988 - $366,555	87,275 Added 8.6%	1,102,209 $4.18 Million
Q1 2021 May 17, 2021	BUY	$2.92 - $5.06 $172,061 - $298,160	58,925 Added 6.16%	1,014,934 $3.44 Million
Q4 2020 Feb 16, 2021	BUY	$2.22 - $3.78 $30,265 - $51,532	13,633 Added 1.45%	956,009 $2.68 Million
Q3 2020 Nov 13, 2020	SELL	$2.39 - $13.08 $249,869 - $1.37 Million	-104,548 Reduced 9.99%	942,376 $2.37 Million
Q2 2020 Aug 14, 2020	BUY	$6.67 - $13.58 $2.03 Million - $4.13 Million	304,312 Added 40.98%	1,046,924 $14.2 Million
Q1 2020 May 15, 2020	BUY	$4.1 - $10.24 $57,363 - $143,267	13,991 Added 1.92%	742,612 $5.63 Million
Q4 2019 Feb 07, 2020	BUY	$3.16 - $6.73 $83,945 - $178,782	26,565 Added 3.78%	728,621 $4.61 Million
Q3 2019 Nov 08, 2019	BUY	$3.55 - $5.4 $189,225 - $287,836	53,303 Added 8.22%	702,056 $2.75 Million
Q2 2019 Aug 09, 2019	BUY	$4.1 - $8.05 $335,433 - $658,594	81,813 Added 14.43%	648,753 $3.14 Million
Q1 2019 May 14, 2019	BUY	$5.41 - $8.73 $36,138 - $58,316	6,680 Added 1.19%	566,940 $4.64 Million
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $1.14 Million - $1.93 Million	210,638 Added 60.25%	560,260 $3.1 Million
Q3 2018 Nov 13, 2018	SELL	$7.44 - $10.65 $244,701 - $350,278	-32,890 Reduced 8.6%	349,622 $3.09 Million
Q2 2018 Aug 08, 2018	BUY	$9.15 - $11.34 $332,977 - $412,673	36,391 Added 10.51%	382,512 $3.82 Million
Q1 2018 May 07, 2018	BUY	$9.53 - $15.68 $476,404 - $783,843	49,990 Added 16.88%	346,121 $3.3 Million
Q4 2017 Jan 17, 2018	BUY	$14.24 - $19.59 $823,043 - $1.13 Million	57,798 Added 24.25%	296,131 $4.4 Million
Q3 2017 Nov 13, 2017	BUY	$13.06 - $19.67 $3.11 Million - $4.69 Million	238,333	238,333 $4.69 Million

Others Institutions Holding AKBA

# of Institutions

127

Shares Held

56.7M

Call Options Held

937K

Put Options Held

743K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $188M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Akebia Therapeutics, Inc. Transaction History